Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network
- 1 May 2007
- journal article
- unknown primary-site-cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (13) , 1747-1752
Abstract
Purpose: Treatment remains poor for many patients with carcinoma of unknown primary site (CUP), and no effective second-line treatment has been identified. Combination inhibition of vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR) with bevacizumab and erlotinib has proved efficacious and well tolerated in other solid tumors. We therefore have evaluated the efficacy and toxicity of this combination in patients with CUP. Patients and Methods: Patients with CUP who either had received previous chemotherapy or were previously untreated with poor-prognosis clinical features were eligible for this study. All patients received bevacizumab 10 mg/kg IV every 2 weeks, along with erlotinib 150 mg orally daily. Patients were re-evaluated after 8 weeks of treatment; those with objective response or stable disease continued treatment until disease progression. Results: Forty-seven (92%) of 51 patients received at least 8 weeks of treatment. Five patients (10%) had partial responses, and 29 patients (61%) had stable disease as the best response. The median survival for the entire group was 7.4 months, with 33% of patients alive at 1 year. This regimen was well tolerated by most patients. Conclusion: The combination of bevacizumab and erlotinib has substantial activity in the treatment of patients with CUP. The median survival is superior to survival previously reported with second-line chemotherapy, and is similar to the results of many first-line chemotherapy trials in this setting. This regimen merits further evaluation in patients with CUP.Keywords
This publication has 20 references indexed in Scilit:
- Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary siteCancer, 2006
- Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary siteCancer, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Development and Validation of a Prognostic Model to Predict the Length of Survival in Patients With Carcinomas of an Unknown Primary SiteJournal of Clinical Oncology, 2002
- Gemcitabine in the Second-Line Therapy of Patients with Carcinoma of Unknown Primary Site: A Phase II Trial of the Minnie Pearl Cancer Research NetworkCancer Investigation, 2001
- Carcinoma of unknown primary siteCancer, 2000
- The Biology of Vascular Endothelial Growth FactorEndocrine Reviews, 1997
- Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.Journal of Clinical Oncology, 1994
- Lack of Value for Cisplatin Added to Mitomycin-Doxorubicin Combination Chemotherapy for Carcinoma of Unknown Primary Site A Randomized TrialAmerican Journal of Clinical Oncology, 1987